Skip to content
Optinose logo — company profile

Optinose

Founded 2010 United States Yardley, United States 146 employees Post-IPO Equity Total: $566.20M Biotechnology, Medical Devices +1

General Information

Company Name Optinose
Founded Year 2010
Location United States Yardley, United States
Founders / Decision Makers
Team member Team member
Employees 146
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Optinose. To contact Optinose, visit optinose.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Optinose compare?

A PDF of Optinose and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Optinose soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Optinose

Optinose is a specialty pharmaceutical company focusing on the development and commercialization of products for patients treated by ear, nose, and throat (ENT) and allergy specialists. Its flagship product, XHANCE®, uses a proprietary Exhalation Delivery System™ (EDS®) to deliver a corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The U.S. Food and Drug Administration (FDA) has already approved XHANCE for the treatment of nasal polyps and, if the pending supplement is approved, it could become the first FDA-approved drug therapy for chronic sinusitis. Established in 2000, Optinose is headquartered in the United States, with a workforce of 141 full-time employees. The company places a strong emphasis on its culture, driven by its core values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance, and Possibility Thinking. Optinose has recently received a $55.00M Post-IPO Equity investment on May 9, 2024 from D. E. Shaw & Co. and Nantahala Capital Management.

Business keywords: pharmaceutical industry, ENT specialists, chronic rhinosinusitis, nasal polyps, FDA approval, Exhalation Delivery System, clinical trials, sNDA submission, drug therapy, employee management, company culture

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $55.00M 2
Nantahala Capital Management, D. E. Shaw & Co.
09 May 2024
Post IPO Equity $50.00M -
21 Nov 2022
Post IPO Debt $150.00M 1
Pharmakon Advisors
12 Sep 2020
Post IPO Equity $54.00M -
21 Nov 2019
Post IPO Debt $100.00M 1
Athyrium Capital Management
02 Jan 2018
Series D $37.00M 3
Avista Capital Partners, Fidelity +1
09 May 2017
Series C $30.00M 3
Avista Capital Partners, The Entrepreneurs' Fund +1
06 Oct 2015
Series C $35.00M 3
Avista Capital Partners, WFD Ventures +1
05 Aug 2014
Private Equity Round $48.50M 2
Avista Capital Partners, WFD Ventures
07 Jun 2010
Seed Round kr6.70M 1
Oxygen House
14 Dec 2002

Optinose Alternatives & Competitors

View All Alternatives
Optinose vs

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer...

Venture round
8 employees
Biotechnology, Life Sciences
Optinose vs
Quince Therapeutics
Quince Therapeutics United States

Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases

Post-IPO Equity
25 employees
Biotechnology, Health Care
Optinose vs
X4 Pharmaceuticals
X4 Pharmaceuticals United States

Enabling a better future for people with rare immune disorders

Post-IPO Debt
137 employees
Biotechnology, Health Care

FAQ About Optinose

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizin...
Optinose was founded in 2010.
Optinose is headquartered in Yardley, United States.
Optinose operates in Biotechnology, Medical Devices and Pharmaceutical. Its work centres on pharmaceutical industry, ENT specialists, chronic rhinosinusitis and nasal polyps.
Optinose has approximately 146 employees.
Optinose has completed 10 funding rounds, raising a total of $566.20M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Optinose include SciTech Development, Inc., Quince Therapeutics, X4 Pharmaceuticals, ADC Therapeutics, Acer Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Optinose and SciTech Development, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Optinose, https://bouncewatch.com/company/optinose, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout